An overall survival analysis of the phase II GALAXY study presented at ESMO GI 2026 suggests that circulating tumor DNA for molecular residual disease tracking could help identify patients with colorectal cancer and liver metastases who are most likely to benefit from adjuvant chemotherapy after surgery. (The ASCO Post)
ctDNA Testing May Identify Who Benefits from Chemotherapy After Liver Metastasis Surgery
The CRC Digest